Every 10-Q that Citius Pharmaceuticals Inc. (CTXR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CTXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTXR filings page.
Citius Pharmaceuticals, Inc. reported its first meaningful commercial activity for LYMPHIR, generating $7.1 million in net revenue for the nine months ended June 30, 2026, with a gross profit of $5.5 million. Total assets were $142.3 million, including $17.0 million of cash, up from $4.3 million at September 30, 2025, largely due to equity financings, warrant exercises and a new term loan at its majority-owned subsidiary Citius Oncology.
The company recorded a nine-month net loss of $49.4 million and used $23.0 million of cash in operating activities. Management cites a “substantial doubt” going-concern uncertainty, estimating current cash resources fund operations only through November 2026 and highlighting the need for additional capital and successful commercialization of LYMPHIR and future products. Citius Oncology incurred about $20.1 million in termination and related fees after its prior bulk drug substance manufacturer ended their agreement, and both Citius Pharma and Citius Oncology received Nasdaq notices for minimum bid-price noncompliance. A term loan of up to $25.0 million (with $10.0 million funded) provides additional liquidity but carries interest of at least 12.75% and is secured by Citius Oncology’s assets.
Citius Pharmaceuticals reported its first meaningful LYMPHIR sales but remains deeply unprofitable and capital constrained. Net revenue reached $5.6M for the six months ended March 31, 2026, generating gross profit of $4.5M. However, total operating expenses of $45.7M, including large general and administrative costs and amortization of in-process R&D, led to a net loss of $37.5M and a loss per share of $1.34.
Cash and cash equivalents were $4.6M with negative working capital of about $23.3M, and operating activities used $14.3M of cash over six months. The company recognized a $3.8M gain from selling New Jersey net operating losses but also recorded about $20.1M of termination-related charges and a $19.7M contract cancellation fee after its LYMPHIR bulk drug substance manufacturer ended the supply agreement and exited microbial production.
Management’s going concern note states there is substantial doubt about Citius’s ability to continue beyond November 2026 without new funding. Subsequent events include a $5.0M registered direct offering at $0.985 per share, approximately $11.5M of Citius Oncology warrant-inducement proceeds, and a loan facility of up to $25.0M for Citius Oncology bearing at least 12.75% interest. Both Citius Pharma and Citius Oncology also received Nasdaq notices for minimum bid-price deficiencies.
Citius Pharmaceuticals reported its first commercial revenue from LYMPHIR in the quarter ended December 31, 2025, generating $3.9M of net revenue and about $3.2M of gross profit. Despite this, the company recorded a net loss of $9.4M and used $13.0M of cash in operating activities, leaving cash and cash equivalents of $7.7M.
Management states that existing cash is expected to fund operations only through May 2026 and that there is “substantial doubt” about the ability to continue as a going concern without additional capital. Citius also received a Nasdaq notice in February 2026 for failing to meet the $1.00 minimum bid price requirement. To support liquidity, Citius and majority‑owned Citius Oncology completed multiple equity and pre‑funded warrant offerings during 2025 and the quarter, significantly increasing shares outstanding and creating a large warrant overhang.
Citius Pharmaceuticals reported no revenues for the periods presented while preparing for the commercial launch of LYMPHIR, an FDA-approved immunotherapy the company expects to launch in the fourth quarter of 2025. The company had $6.09 million in cash and cash equivalents and $17.21 million of inventory (finished goods and work‑in‑process) at June 30, 2025, and total assets of $127.68 million. For the nine months ended June 30, 2025 the company recorded a net loss of $30.99 million and used $14.67 million of cash in operating activities. Net loss per share for the nine months was $3.27 on a weighted average of 9.02 million shares.
Liquidity remains a material issue: working capital was negative roughly $27.2 million at June 30, 2025 and management states available cash is expected to fund operations only through September 2025, creating substantial doubt about the company’s ability to continue as a going concern. Significant near‑term obligations include a $28.4 million license payable and an outstanding Milestone balance to Dr. Reddy’s of $22.5 million (partially deferred by agreement). The company raised net financing proceeds of approximately $16.5 million during the period, entered distribution arrangements to support LYMPHIR commercialization, and subsequently regained Nasdaq compliance.